

## **EBCTCG collaborators, listed alphabetically by institution and then alphabetically by name**

*AARTM 048/13/2000 Multicentre Study Group, Spain*—J A Alberro, B Ballester, P Deulofeu, R Fábregas, M Fraile, J M Gubern, J Janer, A Moral, J L de Pablo, G Peñalva, P Puig, M Ramos, R Rojo, P Santesteban, C Serra, M Solà, L Solarnau, J Solsona, E Veloso, S Vidal.

*ACETBC, Tokyo, Japan*—O Abe, R Abe, K Enomoto, K Kikuchi, H Koyama, H Masuda, Y Nomura, Y Ohashi, K Sakai, K Sugimachi, M Toi, T Tominaga, J Uchino, M Yoshida.

*Addenbrooke's Hospital, Cambridge, UK*—J L Haybittle.

*Anglo-Celtic Cooperative Oncology Group, UK*—C F Leonard.

*ARCOSEIN Group, France*—G Calais, P Garaud.

*ATLAS Trial Collaborative Study Group, Oxford, UK*—V Collett, C Davies, A Delmestri, J Sayer.

*Auckland Breast Cancer Study Group, New Zealand*—V J Harvey, I M Holdaway, R G Kay, B H Mason.

*Australian New Zealand Breast Cancer Trials Group, Sydney, Australia*—J F Forbes, N Wilcken.

*Austrian Breast Cancer Study Group, Vienna, Austria*—M Balic, R Bartsch, C Fesl, F Fitzal, H Fohler, M Gnant, R Greil, R Jakesz, C Marth, B Mlineritsch, G Pfeiler, C F Singer, G G Steger, H Stöger.

*Beatson Oncology Centre, Glasgow, UK*—P Canney, H M A Yosef.

*Belgian Adjuvant Breast Cancer Project, Liège, Belgium*—C Focan.

*Berlin-Buch Akademie der Wissenschaften, Germany*—U Peek.

*Birmingham General Hospital, UK*—G D Oates, J Powell.

*Bordeaux Institut Bergonié, France*—M Durand, L Mauriac.

*Bordet Institute, Brussels, Belgium*—A Di Leo, S Dolci, D Larsimont, J M Nogaret, C Philippon, M J Piccart.

*Bradford Royal Infirmary, UK*—M B Masood, D Parker, J J Price.

*Breast Cancer International Research Group (BCIRG)*—M A Lindsay, J Mackey, M Martin.

*Breast Cancer Study Group of the Comprehensive Cancer Centre, Limburg, Netherlands*—P S G J Hupperets.

*British Association of Surgical Oncology BASO II Trialists, London, UK*—T Bates, R W Blamey, U Chetty, I O Ellis, E Mallon, D A L Morgan, J Patnick, S Pinder.

*British Columbia Cancer Agency, Vancouver, Canada*—C Lohrisch, A Nichol.

*Canadian Cancer Trials Group, Kingston, Ontario, Canada*—V H Bramwell, B E Chen, K Gelmon, P E Goss, M N Levine, W Parulekar, J L Pater, K I Pritchard, L E Shepherd, D Tu, T Whelan.

*Cancer and Leukemia Group B, Washington DC, USA*—D Berry, G Broadwater, C Cirincione, H Muss, L Norton, R B Weiss.

*Cancer Care Ontario, Canada*—H T Abu-Zahra.

*Cancer Research Centre of the Russian Academy of Medical Sciences, Moscow, Russia*—S M Portnoj.

*Cancer Research UK Clinical Trials Unit (CRCTU), NCRI, Birmingham, UK*—S Bowden, C Brookes, J Dunn, I Fernando, M Lee, C Poole, D Rea, D Spooner.

*Cardiff Trialists Group, UK*—P J Barrett-Lee, R E Mansel, I J Monypenny.

*Case Western Reserve University, Cleveland, OH, USA*—N H Gordon.

*Central Oncology Group, Milwaukee, WI, USA*—H L Davis.

*Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, Queen Mary, University of London, UK*—J Cuzick, I Sestak.

*Centre Léon-Bérard, Lyon, France*—Y Lehingue, P Romestaing.

*Centre Paul Lamarque, Montpellier, France*—J B Dubois.

*Centre Régional François Baclesse, Caen, France*—T Delozier, B Griffon, J Mace Leseç'h.

*Centre René Huguenin, Paris, St Cloud, France*—E Brain, B de La Lande, E Mouret-Fourme.

*Centro Oncologico, Trieste, Italy*—G Mustacchi.

*Charles University in Prague, First Faculty of Medicine, Department of Oncology of the First Faculty of Medicine and General Teaching Hospital, Czech Republic*—L Petruzelka, O Pribylova.

*Cheltenham General Hospital, UK*—J R Owen.

*Chemo NO Trial Group, Germany*—N Harbeck, F Jänicke, C Meisner, M Schmitt, C Thomssen.

Chicago University, IL, USA—P Meier.

Chinese Academy of Medical Sciences, Beijing, People's Republic of China (in collaboration with the Oxford PHRU)—Y Shan, Y F Shao, X Wang, D B Zhao (PHRU: Z M Chen, H C Pan).

Christie Hospital and Holt Radium Institute, Manchester, UK—A Howell, R Swindell.

Coimbra Instituto de Oncologia, Portugal—J Albano, C F de Oliveira, H Gervásio, J Gordilho.

Copenhagen Breast Cancer Trials, Copenhagen, Denmark—B Ejlertsen, M-B Jensen, H Johansen, H Mouridsen, T Palshof.

Dana-Farber Cancer Institute, Boston, MA, USA—R S Gelman, J R Harris, D Hayes, C Henderson, C L Shapiro, E Winer.

Danish Breast Cancer Cooperative Group, Copenhagen, Denmark— P Christiansen, B Ejlertsen, M Ewertz, M-B Jensen, H T Mouridsen.

Düsseldorf University, Germany—T Fehm, H J Trampisch.

Dutch Working Party for Autologous Bone Marrow Transplant in Solid Tumours, Amsterdam & Groningen, Netherlands—O Dalesio, E G E de Vries, S Rodenhuis, H van Tinteren.

Eastern Cooperative Oncology Group, Boston, MA, USA—R L Comis, N E Davidson, R Gray, N Robert, G Sledge, L J Solin, J A Sparano, D C Tormey, W Wood.

Edinburgh Breast Unit, UK—D Cameron, U Chetty, J M Dixon, P Forrest, W Jack, I Kunkler.

Elim Hospital, Hamburg, Germany—J Roszbach.

Erasmus MC/Daniel den Hoed Cancer Center, Rotterdam, Netherlands— J G M Klijn, A D Treurniet-Donker, W L J van Putten.

European Institute of Oncology, Milan, Italy—N Rotmensz, U Veronesi, G Viale.

European Organization for Research and Treatment of Cancer, Brussels, Belgium—H Bartelink, N Bijker, J Bogaerts, F Cardoso, T Cufer, J P Julien, E Rutgers, C J H van de Velde.

Evanston Hospital, IL, USA—M P Cunningham.

Finnish Breast Cancer Group, Finland—R Huovinen, H Joensuu.

Fondazione Maugeri Pavia, Italy—A Costa.

Fondazione Michelangelo, Milan, Italy—G Bonadonna, L Gianni, P Valagussa.

Fox Chase Cancer Center, Philadelphia, PA, USA—L J Goldstein.

French Adjuvant Study Group (GFEA), Guyancourt, France—J Bonnetterre, P Fargeot, P Fumoleau, P Kerbrat, E Luporsi, M Namer.

GEICAM, Spanish Breast Cancer Group, Spain—E Carrasco, M Martin, M A Segui.

German Adjuvant Breast Group (GABG), Frankfurt, Germany—W Eiermann, J Hilfrich, W Jonat, M Kaufmann, R Kreienberg, M Schumacher.

German Breast Cancer Study Group (BMFT), Freiburg, Germany—G Bastert, H Rauschecker, R Sauer, W Sauerbrei, A Schauer, M Schumacher.

German Breast Group (GBG), Neu-Isenburg, Germany—J U Blohmer, S D Costa, H Eidtmann, B Gerber, C Jackisch, S Loibl, G von Minckwitz.

Ghent University Hospital, Belgium—A de Schryver, L Vakaet.

GIVIO Interdisciplinary Group for Cancer Care Evaluation, Chieti, Italy—M Belfiglio, A Nicolucci, F Pellegrini, M C Pirozzoli, M Sacco, M Valentini.

Glasgow Victoria Infirmary, UK—C S McArdle, D C Smith, S Stallard.

Groote Schuur Hospital, Cape Town, South Africa—D M Dent, C A Gudgeon, A Hacking, E Murray, E Panieri, ID Werner.

Gruppo Oncologico Clinico Cooperativo del Nord Est, Aviano, Italy—E Galligioni.

Grupo Oncológico Cooperativo del Sur (GOCS), Argentina—B Leone, C T Vallejo, A Zwenger.

Gruppo Oncologico Dell'Italia Meridionale (GOIM), Rome, Italy—M Lopez.

Guadalajara Hospital de 20 Noviembre, Mexico—A Erazo, J Y Medina.

Gunma University, Japan—J Horiguchi, H Takei.

Guy's Hospital, London, UK—I S Fentiman, J L Hayward, R D Rubens, D Skilton.

Heidelberg University I, Germany—H Scheurlen.

Heidelberg University II, Germany—M Kaufmann, H C Sohn.

*Helios Klinikum Berlin-Buch, Germany—M Untch.*  
*Hellenic Breast Surgeons Society, Greece—U Dafni, C Markopoulos.*  
*Hellenic Cooperative Oncology Group, Athens, Greece—U Dafni, G Fountzilias.*  
*Hellenic Oncology Research Group, Greece—D Mavroudis.*  
*Helsinki Deaconess Medical Centre, Finland—P Klefstrom.*  
*Helsinki University, Finland—C Blomqvist, T Saarto.*  
*Hospital del Mar, Barcelona, Spain—M Gallen.*  
*Humanitas Cancer Center, Milan, Italy—C Tinterri.*  
*Innsbruck University, Austria—R Margreiter.*  
*Institut Claudius Regaud, Toulouse, France—B de Lafontan, J Mihura, H Roché.*  
*Institut Curie, Paris, France—B Asselain, R J Salmon, J R Vilcoq.*  
*Institut Gustave-Roussy, Paris, France—F André, R Arriagada, S Delalogue, C Hill, S Koscielny, S Michiels, C Rubino.*  
*Institute of Cancer Research Clinical Trials and Statistics Unit (ICR-CTSU, NCR), UK—R A'Hern, J Bliss, P Ellis, L Kilburn, J R Yarnold.*  
*Integraal Kankercentrum, Amsterdam, Netherlands—J Benraadt, M Kooi, A O van de Velde, J A van Dongen, J B Vermorcken.*  
*International Breast Cancer Study Group (IBCSG), Bern, Switzerland—M Castiglione, A Coates, M Colleoni, J Collins, J Forbes, R D Gelber, A Goldhirsch, J Lindtner, K N Price, M M Regan, C M Rudenstam, H J Senn, B Thuerlimann.*  
*International Collaborative Cancer Group, Charing Cross Hospital, London, UK—J M Bliss, C E D Chilvers, R C Coombes, E Hall, M Marty.*  
*International Drug Development Institute, Louvain-la-Neuve, Belgium—M Buyse.*  
*International TABLE Study Group, Berlin, Germany—K Possinger, P Schmid, M Untch, D Wallwiener.*  
*IRCCS AOU San Martino – IST Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy—C Bighin, P Bruzzi, L Del Mastro, B Dozin, S Pastorino, P Pronzato, M R Sertoli.*  
*ISD Cancer Clinical Trials Team (incorporating the former Scottish Cancer Therapy Network), Edinburgh, UK—L Foster, W D George, H J Stewart, P Stroner.*  
*Israel NSABC, Tel Aviv, Israel—R Borovik, H Hayat, M J Inbar, T Peretz, E Robinson.*  
*Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy—T Camerini, F Formelli, G Martelli, M G Di Mauro, P Valagussa.*  
*Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Italy—F Perrone.*  
*Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Italy—D Amadori.*  
*Italian Cooperative Chemo-Radio-Surgical Group, Bologna, Italy—A Martoni, F Pannuti.*  
*Italian Oncology Group for Clinical Research (GOIRC), Parma, Italy— R Camisa, A Musolino, R Passalacqua.*  
*Japan Clinical Oncology Group—Breast Cancer Study Group, Japan—H Iwata, T Shien.*  
*Japanese Foundation for Multidisciplinary Treatment of Cancer, Tokyo, Japan—O Abe, T Ikeda, K Inokuchi, K Kikuchi, K Sawa.*  
*Kawasaki Medical School, Japan—H Sonoo.*  
*Klinikum Bayreuth, Germany—M Sadoon, A H Tulusan.*  
*Kobe Breast Cancer Oncology Group, Japan—N Kohno, M Miyashita, S Takao.*  
*Korean Cancer Study Group (KCSG), Seoul, South Korea—J.-H Ahn, K H Jung.*  
*Krakow Institute of Oncology, Poland—S Korzeniowski, J Skolyszewski.*  
*Kumamoto University Group, Japan—M Ogawa, J Yamashita.*  
*Leiden University Medical Center, Netherlands—E Bastiaannet, G J Liefers, C J H van de Velde.*  
*Leuven Akademisch Ziekenhuis, Gasthuisberg, Belgium—R Christiaens, P Neven, R Paridaens, W Van den Bogaert.*  
*Ludwig-Maximilians University, Munich, Germany—S Braun.*  
*Marseille Laboratoire de Cancérologie Biologique APM, France—P Martin, S Romain.*

*Medical University Vienna – General Hospital - Department of Obstetrics and Gynaecology and Department of Medicine I, Vienna, Austria*—M Janauer, M Seifert, P Sevelda, C C Zielinski.

*Memorial Sloan-Kettering Cancer Center, New York, NY, USA*—T Hakes, C A Hudis, L Norton, R Wittes.

*Metaxas Memorial Cancer Hospital, Athens, Greece*—G Giokas, D Kondylis, B Lissaios.

*Mexican National Medical Center, Mexico City, Mexico*—R de la Huerta, M G Sainz.

*National Cancer Center, Goyang, South Korea*—J Ro.

*National Cancer Institute, Bethesda, MD, USA*—K Camphausen, D Danforth, A Lichter, M Lippman, D Smart, S Steinberg.

*National Cancer Institute of Bari, Italy*—C D’Amico, M Lioce, A Paradiso.

*National Kyushu Cancer Center, Japan*—Y Nomura, S Ohno.

*National Surgical Adjuvant Breast and Bowel Project (NSABP), Pittsburgh, PA, USA*—S Anderson, G Bass, A Brown (deceased), J Bryant (deceased), J Costantino, J Dignam, B Fisher, C Geyer, E P Mamounas, S Paik, C Redmond, S Swain, L Wickerham, N Wolmark.

*National Surgical Adjuvant Study Group (N-SAS-BC), Japan*—T Aihara, Y Hozumi, Y Nomura.

*Nolvadex Adjuvant Trial Organisation, London, UK*—M Baum, I M Jackson (deceased), M K Palmer.

*North Central Cancer Treatment Group, Mayo Clinic, Rochester, MN, USA*—E Perez, J N Ingle, V J Suman.

*North Sweden Breast Cancer Group, Umeå, Sweden*—N O Bengtsson, S Emdin, H Jonsson.

*North-West Oncology Group (GONO), Italy*—L Del Mastro, M Venturini.

*North-Western British Surgeons, Manchester, UK*—J P Lythgoe, R Swindell.

*Northwick Park Hospital, London, UK*—M Kissin.

*Norwegian Breast Cancer Group, Oslo, Norway*—B Erikstein, E Hannisdal, A B Jacobsen, K V Reinertsen, J E Varhaug.

*Norwegian Radium Hospital, Oslo, Norway*—B Erikstein, S Gundersen, M Hauer-Jensen, H Høst, A B Jacobsen, R Nissen-Meyer.

*Nottingham City Hospital, UK*—R W Blamey, A K Mitchell, D A L Morgan, J F R Robertson.

*Oita Prefectural Hospital, Japan*—H Ueo.

*Oncofrance, Paris, France*—M Di Palma, G Mathé (deceased), J L Misset.

*Ontario Clinical Oncology Group, Hamilton, Canada*—M Levine, K I Pritchard, T Whelan.

*Osaka City University, Japan*—K Morimoto.

*Osaka National Hospital, Japan*—K Sawa, Y Takatsuka.

*Oxford Radcliffe Hospitals NHS Trust, Churchill Hospital, Oxford, UK*—E Crossley, A Harris, D Talbot, M Taylor.

*Parma Hospital, Italy*—G Cocconi, B di Blasio.

*Petrov Research Institute of Oncology, St Petersburg, Russia*—V Ivanov, R Paltuev, V Semiglazov.

*Piedmont Oncology Association, Winston-Salem, NC, USA*—J Brockschmidt, M R Cooper.

*Population Health Research Unit (PHRU), Nuffield Department of Population Health (NDPH), Oxford, UK (ie, members of the PHRU-based EBCTCG Secretariat)*—C Boddington, R Bradley, J Braybrooke, J A Burrett, M Clarke, D Cutter, C Davies, D Dodwell, F Duane, V Evans, L Gettins, J Godwin, R Gray, S James, A Kerr, H Liu, E MacKinnon, G Mannu, P McGale, T McHugh, P Morris, H C Pan, R Peto, S Read, C Taylor, Y Wang, Z Wang.

*Pretoria University, South Africa*—C I Falkson.

*ProBONE study group, Marburg, Germany*—P Hadji.

*Royal Marsden NHS Trust, London and Sutton, UK*—R A’Hern, M Dowsett, A Makris, M Parton, K Pennert, T J Powles, I E Smith, J R Yarnold.

*St George’s Hospital, London, UK*—J C Gazet.

*St George Hospital, Sydney, Australia*—L Browne, P Graham.

*St Luke’s Hospital, Dublin, Ireland*—N Corcoran.

*SABRE trial group (international)*—G Clack, C Van Poznak.

*Sardinia Oncology Hospital A Businico, Cagliari, Sardinia*—N Deshpande, L di Martino.

*SASIB International Trialists, Cape Town, South Africa*—P Douglas, A Hacking, H Høst, A Lindtner, G Notter.

*Saskatchewan Cancer Foundation, Regina, Canada*—A J S Bryant, G H Ewing, L A Firth, J L Krushen-Kosloski.

*Scandinavian Adjuvant Chemotherapy Study Group, Oslo, Norway*—R Nissen-Meyer.

*South Sweden Breast Cancer Group, Lund, Sweden*—H Anderson, F Killander, P Malmström, L Rydén.

*South-East Sweden Breast Cancer Group, Linköping, Sweden*—L-G Arnesson, J Carstensen, M Dufmats, H Fohlin, B Nordenskjöld, M Söderberg.

*South-Eastern Cancer Study Group and Alabama Breast Cancer Project, Birmingham, AL, USA*—J T Carpenter.

*Southampton Oncology Centre, UK*—N Murray, G T Royle, P D Simmonds.

*Southwest Oncology Group, San Antonio, TX, USA*—K Albain, W Barlow, J Crowley, D Hayes, J Gralow, G Hortobagyi, R Livingston, S Martino, C K Osborne, P M Ravdin.

*Stockholm Breast Cancer Study Group, Sweden*—J Bergh, T Bondesson, F Celebioglu, K Dahlberg, T Fornander, I Fredriksson, J Frisell, E Göransson, M Iiristo, U Johansson, E Lenner, L Löfgren, P Nikolaidis, L Perbeck, S Rotstein, K Sandelin, L Skoog, G Svane, E af Trampe, C Wadström.

*SUCCESS-Study Group, University of Düsseldorf, Germany*—W Janni.

*Swiss Group for Clinical Cancer Research (SAKK), Bern, and OSAKO, St Gallen, Switzerland*—M Castiglione, A Goldhirsch, R Maibach, H J Senn, B Thürlimann.

*Tamoxifen Exemestrane Adjuvant Multinational (TEAM) trial*—E Bastiaannet, P Hadji, Y Hozumi, D Rea, C J H van de Velde.

*Tampere University Hospital, Finland*—K Holli, K Rouhento.

*Tel Aviv Sourasky Medical Center, Sackler School of Medicine, Tel Aviv University, Israel*—T Safra.

*Tel Aviv University, Israel*—H Brenner, A Hercbergs.

*Tokyo Cancer Institute Hospital, Japan*—M Yoshimoto.

*Toronto-Edmonton Breast Cancer Study Group, Canada*—A H G Paterson, K I Pritchard.

*Toronto Princess Margaret Hospital, Canada*—A Fyles, J W Meakin, T Panzarella, K I Pritchard.

*Tunis Institut Salah Azaiz, Tunisia*—J Bahi.

*UCBG, French Breast Cancer Intergroup UNICANCER, France*—S Delaloge, J Lemonnier, A L Martin.

*UK Multicentre Cancer Chemotherapy Study Group, London, UK*—M Reid, M Spittle.

*UK/ANZ DCIS Trial*—H Bishop, N J Bundred, J Cuzick, I O Ellis, I S Fentiman, J F Forbes, S Forsyth, W D George, S E Pinder, I Sestak.

*UK/Asia Collaborative Breast Cancer Group, London, UK*—G P Deutsch, R Gray, D L W Kwong, V R Pai, R Peto, F Senanayake.

*University and Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy on behalf of GROCTA trialists*—F Boccardo, A Rubagotti.

*University College London, UK*—M Baum, S Forsyth, A Hackshaw, J Houghton, J Ledermann, K Monson, JS Tobias.

*University Federico II, Naples, Italy*—C Carlomagno, M De Laurentiis, S De Placido.

*University of Edinburgh, UK*—L Williams.

*University of Leeds, UK*—R Bell, D Cameron, R E Coleman, D Dodwell, S Hinsley, H C Marshall.

*University of Michigan, USA*—D Hayes, L J Pierce.

*University of Saarland, Germany*—E Solomayer.

*University of Sheffield, UK*—R E Coleman, J M Horsman, J Lester, M C Winter.

*University of Texas MD Anderson Cancer Center, Houston, TX, USA*—A U Buzdar, L Hsu.

*University of Wisconsin, USA*—R R Love.

*Uppsala-Örebro Breast Cancer Study Group, Sweden*—J Ahlgren, H Garmo, L Holmberg, G Liljegren, H Lindman, F Wärnberg.

*U.S. Oncology, Houston, USA*—L Asmar, S E Jones.

*Washington University, St Louis, Missouri, USA*—R Aft.

*West German Study Group (WSG), Germany*—O Gluz, N Harbeck, C Liedtke, U Nitz.

*West of Scotland Breast Trial Group, Glasgow, UK—A Litton.*

*West Sweden Breast Cancer Study Group, Gothenburg, Sweden—A Wallgren, P Karlsson, B K Linderholm.*

*Western Cancer Study Group, Torrance, CA, USA—R T Chlebowski.*

*Würzburg University, Germany—H Caffier.*

*Z-FAST, ZO-FAST & E-ZO-FAST study groups (international)—A M Brufsky, R E Coleman, H A Llombart, on behalf of Novartis Pharmaceuticals.*

21 July 2017